Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Risk of posttransplant lymphoproliferative disorder associated with use of belatacept.

Martin ST, Powell JT, Patel M, Tsapepas D.

Am J Health Syst Pharm. 2013 Nov 15;70(22):1977-83. doi: 10.2146/ajhp120770. Review.

PMID:
24173007
[PubMed - indexed for MEDLINE]
2.

Belatacept-based regimens versus a cyclosporine A-based regimen in kidney transplant recipients: 2-year results from the BENEFIT and BENEFIT-EXT studies.

Larsen CP, Grinyó J, Medina-Pestana J, Vanrenterghem Y, Vincenti F, Breshahan B, Campistol JM, Florman S, Rial Mdel C, Kamar N, Block A, Di Russo G, Lin CS, Garg P, Charpentier B.

Transplantation. 2010 Dec 27;90(12):1528-35. doi: 10.1097/TP.0b013e3181ff87cd.

PMID:
21076381
[PubMed - indexed for MEDLINE]
3.

Belatacept in kidney transplantation.

Wojciechowski D, Vincenti F.

Curr Opin Organ Transplant. 2012 Dec;17(6):640-7. doi: 10.1097/MOT.0b013e32835a4c0d. Review.

PMID:
23044530
[PubMed - indexed for MEDLINE]
4.

Risk evaluation and mitigation strategies: a focus on belatacept.

Sam T, Gabardi S, Tichy EM.

Prog Transplant. 2013 Mar;23(1):64-70. doi: 10.7182/pit2013122.

PMID:
23448823
[PubMed - indexed for MEDLINE]
5.

Belatacept: a new biologic and its role in kidney transplantation.

Su VC, Harrison J, Rogers C, Ensom MH.

Ann Pharmacother. 2012 Jan;46(1):57-67. doi: 10.1345/aph.1Q537. Epub 2012 Jan 3. Review.

PMID:
22215686
[PubMed - indexed for MEDLINE]
6.

Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys.

Pestana JO, Grinyo JM, Vanrenterghem Y, Becker T, Campistol JM, Florman S, Garcia VD, Kamar N, Lang P, Manfro RC, Massari P, Rial MD, Schnitzler MA, Vitko S, Duan T, Block A, Harler MB, Durrbach A.

Am J Transplant. 2012 Mar;12(3):630-9. doi: 10.1111/j.1600-6143.2011.03914.x. Epub 2012 Feb 2.

PMID:
22300431
[PubMed - indexed for MEDLINE]
Free Article
7.

Belatacept-versus cyclosporine-based immunosuppression in renal transplant recipients with pre-existing diabetes.

Rostaing L, Neumayer HH, Reyes-Acevedo R, Bresnahan B, Florman S, Vitko S, Heifets M, Xing J, Thomas D, Vincenti F.

Clin J Am Soc Nephrol. 2011 Nov;6(11):2696-704. doi: 10.2215/CJN.00270111. Epub 2011 Sep 15.

PMID:
21921152
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Belatacept utilization recommendations: an expert position.

Grinyó JM, Budde K, Citterio F, Charpentier B.

Expert Opin Drug Saf. 2013 Jan;12(1):111-22. doi: 10.1517/14740338.2013.748747. Epub 2012 Dec 4. Review.

PMID:
23206310
[PubMed - indexed for MEDLINE]
9.

A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).

Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial Mdel C, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyó J.

Am J Transplant. 2010 Mar;10(3):547-57. doi: 10.1111/j.1600-6143.2010.03016.x.

PMID:
20415898
[PubMed - indexed for MEDLINE]
Free Article
10.

Biological agents in kidney transplantation: belatacept is entering the field.

Wéclawiak H, Kamar N, Ould-Mohamed A, Cardeau-Desangles I, Rostaing L.

Expert Opin Biol Ther. 2010 Oct;10(10):1501-8. doi: 10.1517/14712598.2010.514901. Review.

PMID:
20726688
[PubMed - indexed for MEDLINE]
11.

Belatacept: a novel biologic for maintenance immunosuppression after renal transplantation.

Martin ST, Tichy EM, Gabardi S.

Pharmacotherapy. 2011 Apr;31(4):394-407. doi: 10.1592/phco.31.4.394. Review.

PMID:
21449628
[PubMed - indexed for MEDLINE]
12.

A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study).

Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP.

Am J Transplant. 2010 Mar;10(3):535-46. doi: 10.1111/j.1600-6143.2009.03005.x.

PMID:
20415897
[PubMed - indexed for MEDLINE]
Free Article
13.

An integrated safety profile analysis of belatacept in kidney transplant recipients.

Grinyó J, Charpentier B, Pestana JM, Vanrenterghem Y, Vincenti F, Reyes-Acevedo R, Apanovitch AM, Gujrathi S, Agarwal M, Thomas D, Larsen CP.

Transplantation. 2010 Dec 27;90(12):1521-7. doi: 10.1097/TP.0b013e3182007b95.

PMID:
21088650
[PubMed - indexed for MEDLINE]
14.

Belatacept: a novel immunosuppressive agent for kidney transplant recipients.

Charpentier B.

Expert Rev Clin Immunol. 2012 Nov;8(8):719-28. doi: 10.1586/eci.12.79.

PMID:
23167683
[PubMed - indexed for MEDLINE]
15.

Belatacept : a new biological agent for maintenance immunosuppression in kidney transplantation.

Arora S, Tangirala B, Osadchuk L, Sureshkumar KK.

Expert Opin Biol Ther. 2012 Jul;12(7):965-79. doi: 10.1517/14712598.2012.683522. Epub 2012 May 8. Review.

PMID:
22564126
[PubMed - indexed for MEDLINE]
16.

Safety of belatacept bridging immunosuppression in hepatitis C-positive liver transplant recipients with renal dysfunction.

LaMattina JC, Jason MP, Hanish SI, Ottmann SE, Klassen DK, Potosky D, Hutson WR, Barth RN.

Transplantation. 2014 Jan 27;97(2):133-7. doi: 10.1097/01.TP.0000438635.44461.2e.

PMID:
24342980
[PubMed - indexed for MEDLINE]
17.

Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.

Rostaing L, Massari P, Garcia VD, Mancilla-Urrea E, Nainan G, del Carmen Rial M, Steinberg S, Vincenti F, Shi R, Di Russo G, Thomas D, Grinyó J.

Clin J Am Soc Nephrol. 2011 Feb;6(2):430-9. doi: 10.2215/CJN.05840710. Epub 2010 Nov 4.

PMID:
21051752
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Long-term exposure to belatacept in recipients of extended criteria donor kidneys.

Charpentier B, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y, Matas A, Zhang R, Mühlbacher F, Pupim L, Florman S.

Am J Transplant. 2013 Nov;13(11):2884-91. doi: 10.1111/ajt.12459. Epub 2013 Sep 18.

PMID:
24103072
[PubMed - indexed for MEDLINE]
19.

Belatacept: in adult kidney transplant recipients.

Garnock-Jones KP.

BioDrugs. 2012 Dec 1;26(6):413-24. doi: 10.2165/11208900-000000000-00000. Review.

PMID:
22928660
[PubMed - indexed for MEDLINE]
20.

Costimulation targeting therapies in organ transplantation.

Gandhi AM, Fazli U, Rodina V, Qazi YA.

Curr Opin Organ Transplant. 2008 Dec;13(6):622-6. doi: 10.1097/MOT.0b013e3283193beb. Review.

PMID:
19060553
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk